The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma by van der Vegt, B. et al.
The expression pattern of MUC1 (EMA) is related to tumour
characteristics and clinical outcome of invasive ductal breast
carcinoma
Bvan der Vegt, M A Jde Roos,
1 JL Peterse,
2*C Patriarca,
3 JHilkens,
4 GH de Bock
5& JWesseling
2
Department of Pathology and
1Department of Surgical Oncology, University Medical Centre Groningen, University of
Groningen and
2Department of Pathology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam,
the Netherlands,
3Department of Pathology, Azienda Ospedaliera di Melegnano, Milan, Italy,
4Division of Tumour Biology,
the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam and
5Department of Epidemiology,
University Medical Centre Groningen, University of Groningen, the Netherlands
Date of submission 27 September 2006
Accepted for publication 9 February 2007
van der Vegt B, de Roos M A J, Peterse J L, Patriarca C, Hilkens J, de Bock G H & Wesseling J
(2007) Histopathology 51, 322–335
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical
outcome of invasive ductal breast carcinoma
Aims: To clarify MUC1 patterns in invasive ductal
breast carcinoma and to relate them to clinicopatho-
logical parameters, coexpression of other biological
markers and prognosis.
Methods and results: Samples from 243 consecutive
patients with primary ductal carcinoma were incor-
porated into tissue microarrays (TMAs). Slides were
stained for MUC1, oestrogen receptor (ER), progesterone
receptor (PR), Her2 ⁄ neu, p53 and cyclin D1. Apical
membrane MUC1 expression was associated with
smaller tumours (P ¼ 0.001), lower tumour grades
(P<0.001), PR positivity (P ¼ 0.003) and increased
overall survival (OS; P ¼ 0.030). Diffuse cytoplasmic
MUC1 expression was associated with cyclin D1 positiv-
ity(P ¼ 0.009)andincreasedrelapse-freesurvival(RFS;
P ¼ 0.034). Negativity for MUC1 was associated with
ER negativity (P ¼ 0.004), PR negativity (P ¼ 0.001)
and cyclin D1 negativity (P ¼ 0.009). In stepwise
multivariate analysis MUC1 negativity was an inde-
pendent predictor of both RFS [hazard ratio (HR) 3.5,
95% conﬁdence interval (CI) 1.5, 8.5; P ¼ 0.005] and
OS (HR 14.7, 95% CI 4.9, 44.1; P < 0.001).
Conclusions: The expression pattern of MUC1 in inva-
sive ductal breast carcinoma is related to tumour
characteristics and clinical outcome. In addition, nega-
tive MUC1 expression is an independent risk factor
for poor RFS and OS, besides ‘classical’ prognostic
indicators.
Keywords: breast carcinoma, ductal, immunohistochemistry, MUC1, prognosis, tissue microarray
Abbreviations: BSA, bovine serum albumin; CI, conﬁdence interval; DCIS, ductal carcinoma in situ; ER, oestrogen
receptor; HR, hazard ratio; OS, overall survival; PBS, phosphate-buffered saline; PR, progesterone receptor;
RFS, relapse-free survival; TMA, tissue microarray
Introduction
MUC1 (episialin, epithelial membrane antigen, CA15-3
antigen) is a highly O-glycosylated mucin-like trans-
membrane glycoprotein encoded by a gene on chromo-
some 1q21.
1 This protein has a very large extra-
cellular domain consisting mainly of 20 amino acid
tandem repeats, a transmembrane domain and a
cytoplasmic tail.
2–4
In most normal glandular epithelial cells, MUC1 is
expressed on the apical surface.
5 In vitro and in vivo
studies have described cell adhesion inhibition as well as
increased metastatic and invasive potential of tumour
cells associated with overexpression of MUC1.
6–8 In
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Histopathology 2007, 51, 322–335. DOI: 10.1111/j.1365-2559.2007.02757.xMUC1-deﬁcient mice primary breast tumours have a
signiﬁcantly lower growth rate.
9 Overexpression of an
underglycosylated form of MUC1 occurs in nearly all
breast carcinomas.
10–12
Using numerous different antibodies and scoring
methods, many authors have described correlations
between MUC1 expression and oestrogen receptor (ER)
status, grade of differentiation and prognosis.
13–15 In
contrast with the in vitro work, most of these studies
have shown a better outcome for patients overexpress-
ing MUC1. Four studies, however, found no relation
between MUC1 expression and outcome.
16–19 These
differences may be explained by the complex scoring
system used, the different afﬁnity of the applied
antibodies for the glycosylated isoforms of MUC1 and
the wide range of histopathological phenotypes of
breast carcinoma with different clinical and prognostic
implications.
20
Therefore, we used a monoclonal antibody directed
at the protein backbone of MUC1 (mAb 214D4), which
is relatively insensitive to the degree and make-up of
glycosylation of the molecule
21 to study ﬁve patterns of
MUC1 expression in primary ductal carcinomas which
were predeﬁned by two of the authors (C.P and J.L.P).
To test the potential of this scoring method, it was
applied to a set of primary invasive ductal breast
carcinomas (not otherwise speciﬁed) arranged in a
tissue microarray (TMA) and the MUC1 expression
patterns were related to clinicopathological parame-
ters, a series of well established biological markers and
prognosis. This scoring method has also been applied to
a set of ductal carcinomas in situ (DCIS).
22
Materials and methods
patients
Consecutive patients (n ¼ 243) treated for a primary
operable invasive ductal carcinoma of the breast
(not otherwise speciﬁed) at the University Medical
Centre Groningen between January 1996 and Decem-
ber 2001 were included in this study. Patient and
tumour characteristics and data on follow-up were
obtained retrospectively from hospital records and are
summarized in Table 1. The median follow-up was
60.5 months (range 0.4–108.2). Follow-up was per-
formed according to the regional follow-up guide-
lines (http://www.ikcnet.nl/page.php?id=97). During
follow-up 12 patients developed a local recurrence
after a median follow-up of 26.7 months. Thirty-three
patients developed distant metastasis after a median
follow-up of 36.7 months. In total, 41 patients presen-
ted with a relapse with a median relapse-free survival
(RFS) of 27.3 months; 20 patients died due to breast
cancer with a median overall survival (OS) of
34.1 months.
Table 1. Patient and tumour characteristics
n %
Age at diagnosis, median (range) 58 (27–89)
Menopausal status
Premenopausal 75 30.9
Postmenopausal 168 69.1
Family history
Positive 34 14.0
Negative 157 64.6
Unknown 52 21.4
Therapy
Breast-conserving therapy 145 59.6
Mastectomy 98 44.9
Axillary nodal status
Negative 131 53.9
Positive 107 44.0
Not assessed 5 2.1
Pathological tumour size (mm),
median (range)
20 (2–140)
Pathological tumour stage
T1 109 44.9
T2 109 44.9
T3 18 7.4
Unknown 7 2.9
Grade of differentiation
I 57 23.5
II 110 45.3
III 75 30.9
Missing 1 0.4
Adjuvant chemotherapy
Yes 61 25.1
No 182 74.9
Adjuvant hormonal therapy
Yes 87 35.8
No 156 64.2
n, Number of cases; T1, tumour diameter <20 mm;
T2, tumour diameter ‡20 mm but <50 mm; T3, tumour
diameter ‡ 50 mm.
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From a parafﬁn block of each tumour, three 0.6-mm
core samples of the most representative tumour area
were included in a TMA. The technique of TMA
production has been described and validated for breast
carcinoma by others.
23,24 In brief, the most represen-
tative tumour area was marked on the original
haematoxylin and eosin (H&E)-stained section. Using
this section for orientation, three 0.6-mm core punches
were taken from the selected area in the donor blocks
and mounted in a recipient block, using a manual
TMA device (Beecher Instruments, Silver Springs,
MD, USA).
immunohistochemistry
Immunohistochemistry for MUC1, ER, progesterone
receptor (PR), Her2 ⁄ neu, cyclin D1 and p53 was
performed on these sections. The antibodies and
antigen retrieval methods used are summarized in
Table 2. The immunohistochemical protocol was as
follows: sections were deparafﬁnized in pure xylene,
rehydrated in decreasing concentrations of ethanol
and washed in distilled water. Antigen retrieval was
performed. Endogenous peroxidase was blocked by
incubating in 3% perhydrol for 30 min. The primary
antibody diluted in phosphate-buffered saline (PBS)
containing 1% bovine serum albumin (BSA) was
incubated for 1 h, after which the secondary (1 : 100
diluted in PBS containing 1% BSA and 1% AB-serum)
and tertiary (1 : 100 diluted in PBS containing 1% BSA
and 1% AB-serum) antibodies were incubated for
30 min each. Visualization was performed using the
diaminobenzidine tetrahydrochloride ⁄ peroxidase reac-
tion. Counterstaining was performed using haemat-
oxylin. Sections were dehydrated using increasing
concentrations of alcohol and were mounted.
evaluation of immunohistochemistry
Scoring of immunohistochemistry was performed by
a resident (B.v.d.V.) and randomly veriﬁed by an
experienced pathologist (J.W.). ER, PR, p53 and
cyclin D1 were graded based on the percentage of
tumour cells showing nuclear immunopositivity. ER,
Table 2. Antibodies and antigen retrieval methods
Antibody Clone Supplier Dilution Antigen retrieval
Secondary
antibody Supplier
Tertiary
antibody Supplier
MUC1 214D4 Dr J. Hilkens* 1 : 100 – RAMPO Dako GARPO Dako
ER 6F11 Ventana † Tris–HCl 0.1 M
(pH 9.5) 30 min
98  C microwave
RAMBIO Dako SARBIO Dako
PR 1A6 Ventana † Tris–HCl 0.1 M
(pH 9.5) 30 min
98  C microwave
RAMBIO Dako SARBIO Dako
p53 BP-53-12-1 Biogenix 1 : 800 Tris–HCl 0.1 M
(pH 9.5) 30 min
98  C microwave
RAMBIO Dako SARBIO Dako
Cyclin D1 SP4 Neomarkers 1 : 50 Tris–HCl 0.1 M
(pH 9.5) 30 min
98  C microwave
RAMBIO Dako SARBIO Dako
Her2 ⁄ neu CB11 Ventana † Tris–HCl 0.1 M
(pH 9.5) 30 min
98  C microwave
RAMBIO Dako SARBIO Dako
ER, Oestrogen receptor; PR, progesterone receptor; RAMPO, rabbit antimouse polyclonal; RAMBIO, rabbit antimouse biotin;
GARPO, goat antirabbit polyclonal; SARBIO, swine antirabbit biotin; –, no antigen retrieval neccesary.
*Gift from Dr J. Hilkens, Division of Tumour Biology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital,
Plesmanlaan 121, 10066 CX Amsterdam, the Netherlands.
†Prediluted by supplier.
324 B van der Vegt et al.
  2007 The Authors. Journal compilation   2007 Blackwell Publishing Ltd, Histopathology, 51, 322–335.PR and cyclin D1 were considered positive if nuclear
staining was present in ‡10% of the cells and p53
was considered positive when there were >30% of
positively stained nuclei. Her2 ⁄ neu expression was
graded as recommended by the manufacturerer’s
scoring guidelines: 0, no staining at all or membrane
staining in <10% of tumour cells; 1+, faint ⁄ barely
perceptible partial membrane staining in >10% of
tumour cells; 2+, weak to moderate complete mem-
brane staining in >10% of tumour cells; 3+, intense
complete membrane staining in >10%. Her2 ⁄ neu
was considered positive if the score was 3+. MUC1
was graded according to the ﬁve expression pat-
terns depicted in Figure 1. MUC1 expression was
A
B
C
D
E
Figure 1. MUC1 immunoreac-
tivity patterns as classiﬁed in
this study. A, Entire membrane.
B, Apical. C, Focal cytoplas-
mic. D, Diffuse cytoplasmic.
E, ‘Inside-out’.
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data analysis
Data analysis was performed using the SPSS 12.0.1
statistical package (SPSS Inc., Chicago, IL, USA). v
2
tests were used to evaluate the association of MUC1
expression with clinicopathological parameters and
biological markers. Because this was an exploratory
analysis, a strict signiﬁcance level was used. Only
P-values (uncorrected) <0.01 were included. If
applicable, Fisher’s exact test was used. In a second
analysis, Kaplan–Meier curves were plotted and log-
rank scores were calculated. In this analysis, P < 0.05
was considered to be signiﬁcant. After this, the six
expression patterns were simpliﬁed into three sub-
groups according to expression location: entire mem-
brane, apical membrane and ‘inside-out’ expression
were classiﬁed as membrane expression; diffuse cyto-
plasmic and focal cytoplasmic were classiﬁed as
cytoplasmic expression; tumours negative for MUC1
were classiﬁed as negative. These groups and other
well-established prognostic indicators were entered
into univariate Cox regression analysis to analyse the
relationship with RFS and OS. Variables from the
univariate analysis with a P-value of <0.05 were
then entered in a stepwise multivariate Cox regres-
sion analysis to investigate the relationship with RFS
and OS.
Results
tissue microarray and immunohistochemistry
Of the 243 cases included, the tissue cores of 237 cases
were adequately represented in the TMA. Immuno-
histochemistry could be evaluated in all cases (100%,
n ¼ 237) for MUC1, p53 and cyclin D1, in 235 cases
(99.2%) for Her2 ⁄ neu, in 232 cases (97.9%) for ER
and in 230 cases (97.0%) for PR.
In the assessable cases, MUC1 was expressed in 221
cases (93.2%) showing either a single or a combina-
tion of expression patterns. Sixteen cases (6.8%) did
not show any expression of MUC1. Entire membrane
expression was seen in 48 cases (20.3%). Sixty-four
cases (27.0%) showed apical expression. In 21 cases
(8.9%), focal cytoplasmic expression was seen. The
most common expression was diffuse cytoplasmic
(73.0%, n ¼ 173). ‘Inside-out’ expression was seen
in 23 cases (9.7%), whereas 117 cases (49.4%)
showed a single expression pattern. The most com-
mon single expression pattern was diffuse cytoplasmic
(70.1%, n ¼ 82). One hundred cases (42.2%) showed
a combination of two patterns and four (1.7%)
showed a combination of three expression patterns.
The most common combination of expression patterns
was apical and diffuse cytoplasmic expression (40.3%,
n ¼ 42).
muc1 expression and clinicopathological
parameters
The relationship between MUC1 expression pattern and
clinicopathological parameters is shown in Table 3.
Apical MUC1 expression was associated with smaller
tumours (P ¼ 0.001) and with lower tumour grades
(P<0.001).
muc1 expression and biological markers
Table 4 shows the relationship between MUC1 expres-
sion and other biological markers.
For apical MUC1 expression a signiﬁcant association
with PR (P ¼ 0.003) expression was found. The
association with ER was not signiﬁcant (P ¼ 0.049).
Diffuse cytoplasmic MUC1 expression showed an
association with cyclin D1 (P ¼ 0.009). For ‘inside-
out’ MUC1 expression a non-signiﬁcant association
with ER was found (P ¼ 0.026). Negativity for MUC1
was associated with ER (P ¼ 0.004), PR (P ¼ 0.001)
and cyclin D1 (P ¼ 0.009).
muc1 expression and clinical outcome
Kaplan–Meier survival curves showed no signiﬁcant
correlation between MUC1 expression of the entire
membrane and OS or RFS. Patients with tumours
that had apical MUC1 expression displayed a better
OS (P ¼ 0.030; Figure 2b). No relationship between
focal cytoplasmic MUC1 expression and survival was
found. Patients with tumours that showed diffuse
cytoplasmic MUC1 expression had a better RFS
than those with tumours that did not show such
expression (P ¼ 0.034; Figure 2a). For ‘inside-out’
MUC1 expression, no correlation with survival was
found. MUC1 negativity was signiﬁcantly associated
with worse RFS (P £ 0.001) and OS (P £ 0.001;
Figure 2c,d).
analysis of combinations of muc1 expression
patterns, clinicopathological parameters,
biological markers andc l i n i c a lo u t c o m e
In order to increase the power of the outcome
analysis the expression patterns were simpliﬁed into
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expression. Apical membrane expression and ‘inside-
out’ expression, which were both associated with a
biologically less aggressive proﬁle, were combined
with entire membrane expression and classiﬁed as
membrane expression. Diffuse cytoplasmic expression
was combined with focal cytoplasmic expression and
classiﬁed as cytoplasmic expression. Tumours that did
not show MUC1 expression were classiﬁed as MUC1–.
In order to evaluate the relation between these three
types of MUC1 expression and RFS and OS, the
dominant type of MUC1 expression in each tumour
was classiﬁed as membrane or cytoplasmic expression,
or as MUC1–. In the case of multiple expression
patterns in one lesion, the dominant type of expres-
sion was deﬁned as that displayed by the largest
percentage of cells.
The results of univariate Cox regression analysis for
RFS are shown in Table 5. Signiﬁcant relations were
found for tumour size [hazard ratio (HR) 2.2, 95%
conﬁdence interval (CI) 1.1, 4.5, P ¼ 0.03 for tumours
between 20 and 50 mm; HR 3.8, 95% CI 1.4, 10.2,
P ¼ 0.009 for tumours >50 mm], tumour grade
(HR 2.3, 95% CI 1.2, 4.2, P ¼ 0.009), MUC1 expres-
sion (HR 3.4, 95% CI 1.5, 8.1, P ¼ 0.005 for MUC1
negativity), Her2 ⁄ neu expression (HR 2.8, 95% CI 1.1,
7.1, P ¼ 0.03), ER expression (HR 0.5, 95% CI 0.3,
1.0, P ¼ 0.05), PR expression (HR 0.4, 95% CI 0.2,
0.7, P < 0.01) and RFS.
Table 6 shows the results from univariate Cox
regression analysis for OS. Signiﬁcant results were
found for tumour size (HR 6.6, 95% CI 1.6, 26.4, P ¼
0.008 for tumours >50 mm), tumour grade (HR 3.6,
95% CI 1.5, 8.7, P ¼ 0.005), axillary lymph node
status (HR 3.0, 95% CI 1.1, 7.8, P ¼ 0.03), receipt of
adjuvant chemotherapy (HR 3.2, 95% CI 1.1, 8.8, P ¼
0.02), MUC1 expression (HR 6.0, 95% CI 2.2, 16.7,
P ¼ 0.001), Her2 ⁄ neu expression (HR 6.3, 95% CI
2.2, 17.5, P < 0.001), ER expression (HR 0.3, 95%
CI 0.1, 0.8, P ¼ 0.02), PR expression (HR 0.4, 95%
CI 0.2, 1.0, P ¼ 0.05) and OS.
The results from the multivariate analysis for RFS
are shown in Table 7. MUC1 expression (HR 4.6, 95%
CI 1.5, 8.5, P ¼ 0.005 for MUC1 negativity) and PR
expression (HR 0.4, 95% CI 0.2, 0.8, P ¼ 0.09) were
signiﬁcant independent predictors of RFS.
Table 8 shows the results from multivariate analy-
sis for OS. Axillary lymph node status (HR 4.7, 95%
CI 1.7, 13.0, P ¼ 0.003), MUC1 expression (HR 14.7,
95% CI 4.9, 44.1, P < 0.001 for MUC1 negativity)
and Her2 ⁄ neu expression (HR 3.7, 95% CI 1.4, 9.5,
P ¼ 0.006) were signiﬁcant independent predictors
of OS.
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This study investigated the relationship between MUC1
expression patterns in invasive ductal carcinoma of the
breast (not otherwise speciﬁed), tumour characteristics,
expression of a series of well-established tumour mark-
ers and clinical outcome. To avoid ambiguous results
due to the heterogeneity of breast cancer, we focused on
this, by far the most common type of breast cancer.
Expression was found in 93.2% of cases. Apical
MUC1 expression was signiﬁcantly associated with
smaller tumours, lower tumour grade, ER positivity
and PR positivity. Diffuse cytoplasmic MUC1 expression
showed a signiﬁcant association with PR and cyclin
D1 positivity. ‘Inside-out’ MUC1 expression was asso-
ciated with ER positivity. Negativity for MUC1 was
signiﬁcantly associated with ER negativity, PR nega-
tivity and cyclin D1 negativity. Patients with apical
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Figure 2. Correlation between the MUC1 expression pattern and relapse-free (A,C) and overall (B,D) survival (Kaplan–Meier method and
log rank test).
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cytoplasmic MUC1-expressing tumours displayed a
signiﬁcantly increased RFS. Patients with tumours
negative for MUC1 showed a signiﬁcantly decreased
RFS and OS on both univariate and multivariate
analysis.
Before discussing the associations found for the
different expression patterns of MUC1 in more detail,
it is important to discuss the antibodies that have been
used to detect MUC1 in various studies. Almost all
anti-MUC1 antibodies used are directed against the
O-glycosylated extracellular MUC1 tandem repeat
domain.
13 However, the degree and make-up of glyco-
sylation may vary extensively among MUC1+ adeno-
carcinomas,
25,26 and the afﬁnity for MUC1 of the vast
majority of these antibodies depends on the extent and
composition of glycosylation.
27,28 As a consequence,
the variety of anti-MUC1 antibodies used to determine
MUC1 expression in breast carcinoma may explain at
least some of the discrepancies between various studies,
as discussed below.
Detecting almost all glycosylated MUC1 isoforms is
important in studying its signiﬁcance for tumour
progression, relationship to other tumour progression
markers and to clinical outcome. Some well-established
functions of MUC1, e.g. inhibition of cell–cell and
cell–extracellular matrix adhesion, are only to a minor
Table 5. Univariate analysis investigating the relation be-
tween pathological and biological characteristics and relapse-
free survival
Pathological and
biological features n (%) HR 95% CI P-value
Tumour size, mm
< 20 109 (46.2) 1
20–50 109 (46.2) 2.2 1.1, 4.5 0.03
> 50 18 (7.6) 3.8 1.4, 10.2 0.009
(n ¼ 236)
Grade*
I and II 167 (69.0) 1
III 75 (31.0) 2.3 1.2, 4.2 0.009
(n ¼ 242)
Axillary lymph node status
Negative 131 (55.0) 1
Positive 107 (45.0) 1.6 0.9, 3.0 0.12
(n ¼ 238)
Adjuvant radiotherapy
No 98 (40.3) 1
Yes 145 (59.7) 1.1 0.6, 2.1 0.76
(n ¼ 243)
Adjuvant chemotherapy
No 123 (50.7) 1
Yes 120 (49.3) 1.4 0.7, 2.5 0.33
(n ¼ 243)
MUC1 expression
Cytoplasmic 144 (60.8)
Membrane 77 (32.5) 1 0.5, 2.0 1.0
Negative 16 (6.7) 3.4 1.5, 8.1 0.005
(n ¼ 237)
Her2 ⁄ neu
Negative 225 (94.5) 1
Positive 13 (5.5) 2.8 1.1, 7.1 0.03
(n ¼ 238)
ER
Negative 54 (22.9) 1
Positive 182 (77.1) 0.5 0.3, 1.0 0.05
(n ¼ 236)
Table 5. (Continued)
Pathological and
biological features n (%) HR 95% CI P-value
PR
Negative 86 (36.9) 1
Positive 147 (63.1) 0.4 0.2, 0.7 0.003
(n ¼ 233)
p53
Negative 226 (93.8) 1
Positive 15 (6.2) 1.5 0.5, 4.3 0.5
(n ¼ 241)
Cyclin D1
Negative 75 (30.9) 1
Positive 168 (69.1) 0.6 0.3, 1.2 0.2
(n ¼ 243)
n, Number of cases; HR, hazard ratio; ER, oestrogen
receptor; PR, progesterone receptor.
*Because of small numbers, grades I and II were combined.
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7,29
For that reason, we used mAb 214D4, a monoclonal
antibody which is also directed to the protein backbone
of the MUC1 repeat domain, but for which afﬁnity is
almost independent of glycosylation status.
21
In normal glandular epithelium, MUC1 is expressed
at the apical surface.
5 For that reason, apical expres-
sion in breast carcinomas (designated ‘pattern B’,
Figure 1) indicates normal routing of MUC1 molecules
and, as a consequence, relatively intact glandular
Table 6. Univariate analysis of the relation of pathological
and biological characteristics with overall survival
Pathological and
biological features n (%) HR 95% CI P-value
Tumour size, mm
< 20 109 (46.2) 1
20–50 109 (46.2) 3.0 1.0, 9.2 0.06
> 50 18 (7.6) 6.6 1.6, 26.4 0.008
(n ¼ 236)
Grade*
I and II 167 (69.0) 1
III 75 (31.0) 3.6 1.5, 8.7 0.005
(n ¼ 242)
Axillary lymph node status
Negative 131 (55.0) 1
Positive 107 (45.0) 3.0 1.1, 7.8 0.03
(n ¼ 238)
Adjuvant radiotherapy
No 98 (40.3) 1
Yes 145 (59.7) 1.0 0.4, 2.4 0.95
(n ¼ 243)
Adjuvant chemotherapy
No 123 (50.7) 1
Yes 120 (49.3) 3.2 1.1, 8.8 0.02
(n ¼ 243)
MUC1 expression
Cytoplasmic 144 (60.8) 1
Membrane 77 (32.5) 0.7 0.2, 2.3 0.6
Negative 16 (6.7) 6.0 2.2, 16.7 0.001
(n ¼ 237)
Her2 ⁄ neu
Negative 225 (94.5) 1
Positive 13 (5.5) 6.3 2.2, 17.5 < 0.001
(n ¼ 238)
ER
Negative 54 (22.9) 1
Positive 182 (77.1) 0.3 0.1, 0.8 0.02
(n ¼ 236)
Table 6. (Continued)
Pathological and
biological features n (%) HR 95% CI P-value
PR
Negative 86 (36.9) 1
Positive 147 (63.1) 0.4 0.2, 1.0 0.05
(n ¼ 233)
p53
Negative 226 (93.8) 1
Positive 15 (6.2) 2.4 0.7, 8.1 0.2
(n ¼ 241)
Cyclin D1
Negative 75 (30.9) 1
Positive 168 (69.1) 0.6 0.2, 1.5 0.3
(n ¼ 243)
n, Number of cases; HR, hazard ratio; ER, oestrogen
receptor; PR, progesterone receptor.
*Because of small numbers, grades I and II were combined.
Table 7. Stepwise multivariate analysis investigating the
relation of pathological and biological characteristics with
relapse-free survival
Characteristics HR 95% CI P-value
MUC1 expression
Cytoplasmic 1
Membrane 1.1 0.5, 2.2 0.8
Negative 3.5 1.5–8.5 0.005
PR
Negative 1
Positive 0.4 0.2, 0.8 0.09
HR, Hazard ratio; 95% CI, 95% conﬁdence interval.
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expression was associated with many indicators of
good prognosis and a better OS. The association with
lower tumour grade,
11,13,15,30 ER
15,30 and PR
30 posi-
tivity and the absence of distant metastasis
15 has been
described. Some authors have found an increased rate
of axillary lymph node negativity
15 and longer RFS for
patients with tumours showing apical MUC1 expres-
sion.
15,31 Our data did not conﬁrm these ﬁndings.
Study size, follow-up and the patients included might
account for this difference, e.g. the study by Hayes et al.
included only node-positive patients. In accordance
with our series, an increase in OS of patients with
tumours showing apical MUC1 expression has been
reported elsewhere.
15,32 One relatively small study
found no association between apical expression and
clinicopathological variables.
33
Entire membrane MUC1 expression (designated ‘pat-
tern A’, Figure 1) is more often seen in mucinous
carcinomas than in ductal carcinomas of no special
type.
12 Although this expression pattern appears to be
the effect of misrouting in the MUC1 pathway, no
unambiguous results on the role of MUC1 expression
on the entire membrane in breast cancer have been
described. Whereas Parham et al. have shown that
high entire membrane expression of MUC1 is associated
with low tumour grade,
17 Rahn et al. have shown the
opposite.
13 The former study also found an association
with positive lymph node status. In the current study
no signiﬁcant associations between MUC1 entire mem-
brane expression and clinicopathological parameters
were found. Entire membrane MUC1 expression did not
associate with clinicopathological characteristics and
outcome in these series. Two other studies that have
looked at the relationship between expression of MUC1
on the entire membrane and outcome have also found
no such relation.
11,17 By combining entire membrane
and cytoplasmic MUC1 expression, Rakha et al. were
able to show a signiﬁcant decrease in OS and RFS in
this group.
15 We did not perform such a subgroup
analysis.
‘Inside-out’ expression (designated ‘pattern E’,
Figure 1) for MUC1 was present in a small percentage
ofthetumoursandhasbeenpreviouslydescribedbytwo
of the authors (C.P., J.L.P.).
34 This pattern is speciﬁc for
invasive micropapillary carcinoma, a subtype of ductal
breast carcinoma with a high potential to metastasize to
axillary lymph nodes.
35 We found no such relationship,
however, nor did we ﬁnd an association between ‘inside
out’ expressionand outcome.The smallnumberof cases
in these series might account for this.
Diffuse cytoplasmic expression of MUC1 was associ-
ated with good prognosis in these series. Previous
reports have linked cytoplasmic expression of MUC1
to ER negativity,
15 high Her2 ⁄ neu expression,
36
decreased RFS
11,15,32 and decreased OS.
15,32 The study
by Lundy et al. found that MUC1 cytoplasmic expres-
sion was related to ER positivity and lower tumour
grade.
33 In this study a positive relationship between
MUC1 diffuse cytoplasmic expression and PR and
cyclin D1 positivity was found, which might be
explained by the common combination of apical and
diffuse cytoplasmic expression in these series. Results
from the subgroup analysis of combined apical and
diffuse cytoplasmic MUC1 expression versus strictly
cytoplasmic MUC1 expression show that tumours with
diffuse cytoplasmic MUC1 expression have a clinico-
pathological proﬁle that is usually associated with a
worse outcome, but that when this is combined with
apical MUC1 expression (i.e. a part of the MUC1 is
routed correctly) this negative effect disappears.
Focal cytoplasmic expression of MUC1 has been
described in lobular carcinoma.
12,37 To our knowledge,
it has not previously been described in ductal carcin-
oma. We did not ﬁnd any relationship between focal
cytoplasmic expression (designated ‘pattern C’) and
any of the investigated variables.
We observed that tumours negative for MUC1 had
a very poor outcome with respect to RFS and OS
(Figure 2C,D). In addition, absence of MUC1 expression
was associated with absence of ER, PR and cyclin D1.
These ﬁndings support the observation by Luna-More
et al. that tumours negative for MUC1 are high grade,
are ER– and PR– and are more frequently associated
with positive axillary lymph nodes.
30 Other studies
Table 8. Stepwise multivariate analysis investigating the
relation of pathological and biological characteristics with
overall survival
Characteristics HR 95% CI P-value
Axillary lymph node status
Negative 1
Positive 4.7 1.7. 13.0 0.003
MUC1 expression
Cytoplasmic 1
Membrane 0.6 0.2, 2.0 0.4
Negative 14.7 4.9, 44.1 < 0.001
Her2 ⁄ neu
Negative 1
Positive 3.7 1.4, 9.5 0.006
HR, Hazard ratio; 95% CI, 95% conﬁdence interval.
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higher tumour grade
13 and poor prognosis.
38 Inﬂam-
matory breast carcinoma patients with MUC1–
tumours had a signiﬁcantly shorter OS.
39 Remarkably,
our MUC1– group of breast carcinomas appears to be a
subgroup with poor prognosis that cannot be identiﬁed
with the common prognostic indicators; for both RFS
and OS survival MUC1 negativity was the strongest
independent predictor (see Tables 7 and 8).
We also performed a study with MUC1 expression in
DCIS (unpublished results). Comparison of those results
with the current study reveals some interesting differ-
ences. The ‘inside-out’ expression pattern is exclusively
seen in invasive ductal carcinomas and not in DCIS.
Also in DCIS, no MUC1– tumours were found. As
mentioned before, the ‘inside-out’ expression pattern is
speciﬁc for invasive micropapillary carcinoma. MUC1–
tumours are a subgroup of tumours that is non-
luminal, non-mucin producing. These tumours are
probably fast growing and aggressive and may not
have a stage of non-invasive growth that can be easily
identiﬁed because of early invasion. Loss of MUC1
might play a role in this process of early invasiveness.
Remarkably, this seems to be in contrast to in vitro and
in vivo data, which show that membranous MUC1
overexpression favours adhesion modulation, invasive
potential and metastatic capacity of tumour cells.
6–9
These effects are very likely due to steric hindrance of
adhesion molecules by the high density of large and
elongated extracellular MUC1 domains at the cell
surface.
7 Undoubtedly, there are more mechanisms
available for acquiring invasive potential, e.g. inacti-
vation of the E-cadherin–b-catenin complex as in
invasive lobular breast carcinoma. To investigate a
potential relationship between MUC1 and E-cadherin
expression, we performed immunohistochemistry for
E-cadherin and b-catenin. However, the immunoreacti-
vity of both proteins was too heterogeneous and
inconsistent for reliable semiquantitative analysis (data
not shown).
In this outcome study, patients were treated in a very
heterogeneous manner (radiotherapy, chemotherapy
and hormonal therapy) and this may have confounded
the results somewhat. However, on univariate analysis
radiotherapy is not a predictor for either OS or RFS.
On multivariate analysis MUC1 negativity remains an
independent predictor of RFS and OS, suggesting an
effect independent of adjuvant therapy. Because of the
many comparisons presented in Tables 3 and 4, only
P-values (uncorrected) <0.01 are presented. It should
be noted that this part of the study was of an
exploratory nature, based on the hypothesis that
MUC1 expression patterns provide added value in
relation to clinicopathological parameters. In addition,
the selection of such clinicopathological parameters
and biomarkers was based on their established role in
the biology of carcinomas and in general breast
carcinoma in particular. Therefore, it is hoped that
the conclusions of this study will contribute to the
optimal determination of the clinical impact of MUC1
expression in invasive ductal breast carcinoma.
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